Evidence map›Paper›PMID 36601751›Full record

ArticleJournal of inherited metabolic disease2023

Clinical and pathological characterization of ophthalmic disease in a canine model of mucopolysaccharidosis type I.

Ariel Nenninger, Gil Ben-Shlomo, Rachel Allbaugh, Bethann Valentine, Elizabeth Snella, Jackie Jens, N Matthew Ellinwood, Jodi Smith

Open access · hybridAbstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Ariel NenningerDepartment of Veterinary Pathology, Iowa State University, Ames, Iowa, USA.
Gil Ben-ShlomoDepartment of Veterinary Clinical Sciences, Iowa State University, Ames, Iowa, USA.
Rachel AllbaughDepartment of Veterinary Clinical Sciences, Iowa State University, Ames, Iowa, USA.
Bethann ValentineDepartment of Animal Science, Iowa State University, Ames, Iowa, USA.
Elizabeth SnellaDepartment of Animal Science, Iowa State University, Ames, Iowa, USA.
Jackie JensDepartment of Animal Science, Iowa State University, Ames, Iowa, USA.
N Matthew EllinwoodDepartment of Animal Science, Iowa State University, Ames, Iowa, USA.
Jodi SmithDepartment of Veterinary Pathology, Iowa State University, Ames, Iowa, USA.ORCID 0000-0001-7952-8024
Iowa State University · US

Funding

Neuroimaging and Neuropathology of Mucopolysaccharidosis IR01NS085381 · NINDS · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI DICKSON, PATRICIA I · 2013 to 2017
$1.6M
NIH HHS R01NS085381NINDS NIH HHS R01 NS085381
6 · The paper itself

Abstract

Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disease caused by α-L-iduronidase enzyme deficiency, resulting in glycosaminoglycan (GAG) accumulation in various cell types, including ocular tissues. Ocular manifestations in humans are common with significant pathological changes including corneal opacification, retinopathy, optic nerve swelling and atrophy, and glaucoma. Available treatments for MPS I are suboptimal and there is limited to no effect in treating the ocular disease. The goal of this study was to characterize the clinical and pathological features of ocular disease in a line of MPS I affected dogs, including changes not previously reported. A total of 22 dogs were studied; 12 MPS I were affected and 10 were unaffected. A subset of each underwent complete ophthalmic examination including slit lamp biomicroscopy, indirect ophthalmoscopy, rebound tonometry, and ultrasonic pachymetry. Globes were evaluated microscopically for morphological changes and GAG accumulation. Clinical corneal abnormalities in affected dogs included edema, neovascularization, fibrosis, and marked stromal thickening. Intraocular pressures were within reference interval for affected and unaffected dogs. Microscopically, vacuolated cells containing alcian blue positive inclusions were detected within the corneal stroma, iris, ciliary body, sclera, and optic nerve meninges of affected dogs. Ganglioside accumulation was identified by luxol fast blue staining in rare retinal ganglion cells. Increased lysosomal integral membrane protein-2 expression was demonstrated within the retina of affected animals when compared to unaffected controls. Results of this study further characterize ocular pathology in the canine model of MPS I and provide foundational data for future therapeutic efficacy studies.

Indexed as

Eye DiseasesLysosomal Storage DiseasesMucopolysaccharidosis IRetinal DiseasesAnimalsDogsGlycosaminoglycansHumansIduronidaseGlycosaminoglycansIduronidasecanineHurlermucopolysaccharidosisocular

Identifiers

PMID36601751
PMCPMC11372224
OpenAlexW4313544008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.